Skip to main content
Top
Published in: BMC Geriatrics 1/2021

Open Access 01-12-2021 | Myocardial Infarction | Research

Outcomes between prediabetes and type 2 diabetes mellitus in older adults with acute myocardial infarction in the era of newer-generation drug-eluting stents: a retrospective observational study

Authors: Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Sang-Ho Park, Byung Gyu Kim, Seunghwan Kim, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang

Published in: BMC Geriatrics | Issue 1/2021

Login to get access

Abstract

Background

The comparative clinical outcomes between prediabetes and type 2 diabetes mellitus (T2DM) in older adults with AMI in the era of newer-generation drug-eluting stents (DES) are limited. We investigated the 2-year clinical outcomes of these patients.

Methods

A total of 5492 AMI patients aged ≥65 years were classified into three groups according to their glycemic status: normoglycemia (group A: 1193), prediabetes (group B: 1696), and T2DM (group C: 2603). The primary outcome was the occurrence of major adverse cardiac events (MACE), defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization. The secondary outcome was stent thrombosis (ST).

Results

The primary and secondary outcomes cumulative incidences were similar between the prediabetes and T2DM groups. In both the prediabetes and T2DM groups, the cumulative incidences of MACE (adjusted hazard ratio [aHR]: 1.373; p = 0.020 and aHR: 1.479; p = 0.002, respectively) and all-cause death or MI (aHR: 1.436; p = 0.022 and aHR: 1.647; p = 0.001, respectively) were significantly higher than those in the normoglycemia group. Additionally, the cumulative incidence of all-cause death in the T2DM group was significantly higher than that in the normoglycemia group (aHR, 1.666; p = 0.003).

Conclusions

In this retrospective study, despite the 2-year clinical outcomes of the patients with prediabetes and T2DM in the older adults were worse than those in the normoglycemia group; they were similar between the prediabetes and T2DM groups. Hence, comparable treatment strategies should be strengthened between prediabetes and T2DM in older adults with AMI.

Trial registration

Retrospectively registered.
Literature
1.
go back to reference Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.CrossRef Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.CrossRef
2.
go back to reference Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 2014;160:517–25.PubMedPubMedCentralCrossRef Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 2014;160:517–25.PubMedPubMedCentralCrossRef
3.
go back to reference Sinclair A, Morley JE, Rodriguez-Mañas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European diabetes working Party for Older People (EDWPOP), and the international task force of experts in diabetes. J Am Med Dir Assoc. 2012;13:497–502.PubMedCrossRef Sinclair A, Morley JE, Rodriguez-Mañas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European diabetes working Party for Older People (EDWPOP), and the international task force of experts in diabetes. J Am Med Dir Assoc. 2012;13:497–502.PubMedCrossRef
5.
go back to reference Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.PubMedCrossRef Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.PubMedCrossRef
6.
go back to reference Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia. 2018;61:1503–16.PubMedPubMedCentralCrossRef Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia. 2018;61:1503–16.PubMedPubMedCentralCrossRef
7.
go back to reference Lee PG, Halter JB. The pathophysiology of hyperglycemia in older adults: clinical considerations. Diabetes Care. 2017;40:444–52.PubMedCrossRef Lee PG, Halter JB. The pathophysiology of hyperglycemia in older adults: clinical considerations. Diabetes Care. 2017;40:444–52.PubMedCrossRef
8.
go back to reference Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38:173–88.PubMedPubMedCentralCrossRef Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38:173–88.PubMedPubMedCentralCrossRef
9.
go back to reference Bauduceau B, Le Floch JP, Halimi S, et al. Cardiovascular complications over 5 years and their association with survival in the GERODIAB cohort of elderly French patients with type 2 diabetes. Diabetes Care. 2018;41:156–62.PubMedCrossRef Bauduceau B, Le Floch JP, Halimi S, et al. Cardiovascular complications over 5 years and their association with survival in the GERODIAB cohort of elderly French patients with type 2 diabetes. Diabetes Care. 2018;41:156–62.PubMedCrossRef
10.
go back to reference American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39(Suppl 1):S13–22.CrossRef American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39(Suppl 1):S13–22.CrossRef
11.
go back to reference George A, Bhatia RT, Buchanan GL, et al. Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PLoS One. 2015;10:e0142045.PubMedPubMedCentralCrossRef George A, Bhatia RT, Buchanan GL, et al. Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PLoS One. 2015;10:e0142045.PubMedPubMedCentralCrossRef
12.
go back to reference Yang SW, Zhou YJ, Nie XM, et al. Effect of abnormal fasting plasma glucose level on all-cause mortality in older patients with acute myocardial infarction: results from the Beijing elderly acute myocardial infarction study (BEAMIS). Mayo Clinic Proc. 2011;86:94–104.CrossRef Yang SW, Zhou YJ, Nie XM, et al. Effect of abnormal fasting plasma glucose level on all-cause mortality in older patients with acute myocardial infarction: results from the Beijing elderly acute myocardial infarction study (BEAMIS). Mayo Clinic Proc. 2011;86:94–104.CrossRef
13.
go back to reference Kok MM, von Birgelen C, Sattar N, et al. Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention. 2018;14:e1049–56.PubMedCrossRef Kok MM, von Birgelen C, Sattar N, et al. Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention. 2018;14:e1049–56.PubMedCrossRef
14.
go back to reference Kim YH, Her AY, Jeong MH, et al. Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: a retrospective observational registry study. Medicine. 2021;100:e24733.PubMedCrossRef Kim YH, Her AY, Jeong MH, et al. Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: a retrospective observational registry study. Medicine. 2021;100:e24733.PubMedCrossRef
15.
go back to reference Preiss D, Thomas LE, Sun JL, et al. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open. 2012;2:e001925.PubMedPubMedCentralCrossRef Preiss D, Thomas LE, Sun JL, et al. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open. 2012;2:e001925.PubMedPubMedCentralCrossRef
16.
go back to reference Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013;165:918–925.e912.PubMedCrossRef Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013;165:918–925.e912.PubMedCrossRef
17.
go back to reference Kim YH, Her AY, Jeong MH, et al. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020;95:E40–55.PubMedCrossRef Kim YH, Her AY, Jeong MH, et al. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020;95:E40–55.PubMedCrossRef
18.
go back to reference Lee SA, Cho SJ, Jeong MH, et al. Hypoglycemia at admission in patients with acute myocardial infarction predicts a higher 30-day mortality in patients with poorly controlled type 2 diabetes than in well-controlled patients. Diabetes Care. 2014;37:2366–73.PubMedCrossRef Lee SA, Cho SJ, Jeong MH, et al. Hypoglycemia at admission in patients with acute myocardial infarction predicts a higher 30-day mortality in patients with poorly controlled type 2 diabetes than in well-controlled patients. Diabetes Care. 2014;37:2366–73.PubMedCrossRef
19.
go back to reference Kim JH, Chae SC, Oh DJ, et al. Multicenter cohort study of acute myocardial infarction in Korea - interim analysis of the Korea acute myocardial infarction registry-National Institutes of Health registry. Circ J. 2016;80:1427–36.PubMedCrossRef Kim JH, Chae SC, Oh DJ, et al. Multicenter cohort study of acute myocardial infarction in Korea - interim analysis of the Korea acute myocardial infarction registry-National Institutes of Health registry. Circ J. 2016;80:1427–36.PubMedCrossRef
22.
go back to reference Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009;119:3207–14.PubMedCrossRef Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009;119:3207–14.PubMedCrossRef
23.
go back to reference Gao W, Zhang Q, Ge H, et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology. 2013;64:554–8.PubMedCrossRef Gao W, Zhang Q, Ge H, et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology. 2013;64:554–8.PubMedCrossRef
24.
go back to reference Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.PubMedCrossRef Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.PubMedCrossRef
25.
go back to reference Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.PubMedCrossRef Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.PubMedCrossRef
26.
go back to reference O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61:e78–e140.PubMedCrossRef O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61:e78–e140.PubMedCrossRef
27.
go back to reference Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the Management of Patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e139–228.PubMedCrossRef Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the Management of Patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e139–228.PubMedCrossRef
28.
go back to reference Kim YH, Her AY, Jeong MH, et al. Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: comparison between STEMI and NSTEMI. Atherosclerosis. 2019;280:166–73.PubMedCrossRef Kim YH, Her AY, Jeong MH, et al. Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: comparison between STEMI and NSTEMI. Atherosclerosis. 2019;280:166–73.PubMedCrossRef
29.
go back to reference Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between Sirolimus and paclitaxel eluting stents?: a systematic review and Meta-analysis of randomized controlled trials. Medicine. 2016;95:e2651.PubMedPubMedCentralCrossRef Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between Sirolimus and paclitaxel eluting stents?: a systematic review and Meta-analysis of randomized controlled trials. Medicine. 2016;95:e2651.PubMedPubMedCentralCrossRef
30.
go back to reference Milanesi A, Weinreb JE. Diabetes in the elderly. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright ©; 2000. p. 2000–21. Milanesi A, Weinreb JE. Diabetes in the elderly. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright ©; 2000. p. 2000–21.
31.
go back to reference Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–9.PubMedCrossRef Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–9.PubMedCrossRef
32.
go back to reference Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study. Lancet. 2012;379:2243–51.PubMedPubMedCentralCrossRef Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study. Lancet. 2012;379:2243–51.PubMedPubMedCentralCrossRef
33.
go back to reference Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56:1489–93.PubMedCrossRef Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56:1489–93.PubMedCrossRef
34.
go back to reference DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108:3b–24b.PubMedCrossRef DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108:3b–24b.PubMedCrossRef
35.
go back to reference Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537–47.PubMedCrossRef Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537–47.PubMedCrossRef
37.
go back to reference Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.PubMedPubMedCentralCrossRef Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.PubMedPubMedCentralCrossRef
38.
go back to reference von Birgelen C, Kok MM, Sattar N, et al. "silent" diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the BIO-RESORT silent diabetes study. JACC Cardiovasc Interv. 2018;11:448–59.CrossRef von Birgelen C, Kok MM, Sattar N, et al. "silent" diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the BIO-RESORT silent diabetes study. JACC Cardiovasc Interv. 2018;11:448–59.CrossRef
39.
go back to reference Chattopadhyay S, George A, John J, et al. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. Diab Vasc Dis Res. 2019;16:489–97.PubMedCrossRef Chattopadhyay S, George A, John J, et al. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. Diab Vasc Dis Res. 2019;16:489–97.PubMedCrossRef
40.
go back to reference Deedwania PC, Ahmed MI, Feller MA, et al. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail. 2011;13:551–9.PubMedPubMedCentralCrossRef Deedwania PC, Ahmed MI, Feller MA, et al. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail. 2011;13:551–9.PubMedPubMedCentralCrossRef
41.
go back to reference Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRef Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRef
42.
go back to reference Oliver MF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med. 2002;112:305–11.PubMedCrossRef Oliver MF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med. 2002;112:305–11.PubMedCrossRef
43.
go back to reference Aljada A, Friedman J, Ghanim H, et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism. 2006;55:1177–85.PubMedCrossRef Aljada A, Friedman J, Ghanim H, et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism. 2006;55:1177–85.PubMedCrossRef
44.
go back to reference Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171–82.PubMedCrossRef Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171–82.PubMedCrossRef
45.
46.
go back to reference Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–3.PubMedCrossRef Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630–3.PubMedCrossRef
47.
go back to reference Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMedCrossRef Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMedCrossRef
48.
go back to reference Carris NW, Magness RR, Labovitz AJ. Prevention of diabetes mellitus in patients with Prediabetes. Am J Cardiol. 2019;123:507–12.PubMedCrossRef Carris NW, Magness RR, Labovitz AJ. Prevention of diabetes mellitus in patients with Prediabetes. Am J Cardiol. 2019;123:507–12.PubMedCrossRef
49.
go back to reference Kim YH, Her AY, Jeong MH, et al. Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study. BMC Cardiovasc Disord. 2021;21:386.PubMedPubMedCentralCrossRef Kim YH, Her AY, Jeong MH, et al. Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study. BMC Cardiovasc Disord. 2021;21:386.PubMedPubMedCentralCrossRef
50.
go back to reference Taniwaki M, Stefanini GG, Räber L, et al. Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. EuroIntervention. 2015;11:391–8.PubMedCrossRef Taniwaki M, Stefanini GG, Räber L, et al. Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. EuroIntervention. 2015;11:391–8.PubMedCrossRef
51.
go back to reference Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, et al. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61:734–8.PubMedCrossRef Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, et al. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61:734–8.PubMedCrossRef
52.
go back to reference Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) Group. Lancet. 1998;352:837–53. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) Group. Lancet. 1998;352:837–53.
Metadata
Title
Outcomes between prediabetes and type 2 diabetes mellitus in older adults with acute myocardial infarction in the era of newer-generation drug-eluting stents: a retrospective observational study
Authors
Yong Hoon Kim
Ae-Young Her
Myung Ho Jeong
Byeong-Keuk Kim
Sung-Jin Hong
Sang-Ho Park
Byung Gyu Kim
Seunghwan Kim
Chul-Min Ahn
Jung-Sun Kim
Young-Guk Ko
Donghoon Choi
Myeong-Ki Hong
Yangsoo Jang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-021-02601-3

Other articles of this Issue 1/2021

BMC Geriatrics 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.